Cara Therapeutics | CARA - El Costo De Ventas





El Costo De Ventas Cambio Fecha
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Assertio Holdings USD 8.89M 2.29M 2024-06
Cara Therapeutics USD 0 0 2025-03
Cassava Sciences USD 3.96M 1.16M 2025-09
Chugai Pharma JPY 92.79B 5.23B 2026-03
Cipla INR 26.32B 2.79B 2026-03
Clal Biotechnology ILS 16.49M 2.64M 2022-06
Compugen USD 3.54M 1.89M 2025-12
CSL USD 3.87B 2.08B 2025-12
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
J&J USD 8.07B 103M 2026-03
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Pacira USD 50.74M 3.89M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
RedHill Biopharma USD 702K 0 2024-06
Supernus Pharmaceuticals USD 49.04M 1.5M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12